CytoSite BioPharma Inc. — Form D/A
CytoSite BioPharma Inc. of SUDBURY, MA, a company, filed a Form D amendment with the SEC on 2020-10-05. The offering totals $5.1M, of which $3.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2020-10-05
- Form: D/A
- Accession: 0001104659-20-112049
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $5.1M
- Amount sold: $3.0M
- Remaining: $2.1M
- Investors: 12
- Date of first sale: 2019-09-10
- Security types: equity
- Revenue range: No Revenues
- SEC file number: 021-349481
Issuer
- Name: CytoSite BioPharma Inc.
- CIK: 0001725090
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2016
- Address: 14 PETERSEN CIRCLE, SUDBURY, MA, 01776
- Phone: 978-460-0695
Officers, directors & promoters (8)
| Name | Role | Location |
|---|
| Michel Chu | Director | Sudbury, MA |
| Robert Gailus | Director | Sudbury, MA |
| James Jenson | Director | Medford, MA |
| Mark Mintun | Director | Sudbury, MA |
| Stephen Sands | Director | Sudbury, MA |
| Ellen Cordo | Executive Officer | Sudbury, MA |
| James Jenson | Executive Officer | Medford, MA |
| Richard Smith | Executive Officer | Denver, CO |
Other filings by this issuer (4)
More